Tidal Investments’s Denali Therapeutics DNLI Stock Holding History

Tidal Investments’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,576	Closed	-$202K	–	895
2021 Q2	$202K	Buy	+2,576	New	+$159K	0.01%	691

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Tidal Investments's DNLI Position: Q3 2021 in Review

Tidal Investments sold out of Denali Therapeutics (DNLI) in Q3 2021, closing a stake of 2,576 shares — an estimated $202K sold.

Tidal Investments first reported a position in DNLI in Q2 2021 and held it in 1 quarter. The position peaked at $202K in Q2 2021. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

Tidal Investments reported no remaining Denali Therapeutics position as of Q3 2021 after selling out during the quarter.
Tidal Investments sold 2,576 Denali Therapeutics shares in Q3 2021, an estimated $202K.
Tidal Investments first reported a position in Denali Therapeutics in Q2 2021 and held it in 1 quarter.
Tidal Investments's Denali Therapeutics position peaked at $202K in Q2 2021.
214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Tidal Investments's 13F filing for Q3 2021, filed 15 Nov 2021.